Emergent Biosolutions
EBS
132 hedge funds and large institutions have $570M invested in Emergent Biosolutions in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 54 increasing their positions, 49 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
26% more capital invested
Capital invested by funds: $451M → $570M (+$119M)
10% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 49
5% more funds holding
Funds holding: 126 → 132 (+6)
2.93% more ownership
Funds ownership: 66.34% → 69.27% (+2.9%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$4.67M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$4.41M |
| 3 |
Morgan Stanley
New York
|
+$2.77M |
| 4 |
Charles Schwab
San Francisco,
California
|
+$2.43M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$4.92M |
| 2 |
Bank of New York Mellon
New York
|
-$2.9M |
| 3 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$1.48M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.05M |
| 5 |
KIA
King Investment Advisors
Houston,
Texas
|
-$1.04M |
EBS Hedge Fund Activity: Q4 2013 in Review
132 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2013, worth a combined $570M — up 26% from $451M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EBS positions and 11 closed out — a net gain of 6 holders — while 54 added to existing stakes and 49 trimmed.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $4.67M. The largest seller was Kingdon Capital Management, cutting an estimated $4.92M.
- 132 institutional investors held Emergent Biosolutions (EBS) as of Q4 2013, up from 126 in Q3 2013.
- Funds reported $570M of Emergent Biosolutions stock for Q4 2013, up 26% quarter-over-quarter.
- 17 funds opened new Emergent Biosolutions positions in Q4 2013 and 11 closed out, a net change of +6 holders.
- The largest Emergent Biosolutions buyer in Q4 2013 was Panagora Asset Management, an estimated $4.67M added.
- The largest Emergent Biosolutions seller in Q4 2013 was Kingdon Capital Management, an estimated $4.92M sold.
Based on aggregated 13F filings for Q4 2013.